Therapeutic drug discovery is a lengthy process. . . posing a formidable challenge for start-ups. Crescenta Biosciences: Pharmaceutical Discovery
The journey of therapeutic drug discovery is a lengthy process, typically spanning 15-20+ years. Characterized by substantial financial investments in the hundreds of millions, it poses a formidable challenge for start-ups. The odds of successfully bringing a new drug to market are less than 1%. However, the potential rewards, both in terms of scientific advancement and the ability to deliver potentially life-saving drugs to patients, are undeniably significant. Crescenta Biosciences Inc., a pioneer in small molecule drug discovery, is dedicated to forging new paths in therapeutic approaches for diseases linked to fatty acid metabolism. At the heart of Crescenta Bioscience’s innovative efforts lies a discovery platform grounded in a groundbreaking concept. This approach enables the manipulation of biological functions associated with “fatty acid interacting proteins,” correcting metabolic imbalances and offering expansive therapeutic possibilities. The company has assembled a portfolio of first-in-class drug candidates for the treatment of diseases with major unmet medical needs, particularly those related to metabolism and aging. Crescenta’s goal is to advance its pipeline into clinical development and commercialization. Emre Koyuncu, a Fellow in Molecular Biology and Virology at Princeton University is a Co- Founder & CEO of the company. During his tenure at Princeton, Dr. Koyuncu collaborated
with distinguished innovators, including Nobel Prize winner Dr. David McMillan, Dr. Tom Shenk, revered as the “Father of Modern Microbiology”, and Harvard professor, Dr. Han Kim, who joined Koyuncu to co-found Crescenta Biosciences. Together, this formidable team is committed to advancing the frontiers of pharmaceutical innovation and determined to overcome the challenges inherent in the pursuit of groundbreaking therapeutic solutions. Seeking a laboratory to move his research to Irvine, Dr. Koyuncu found University Lab Partners to be a perfect fit. The transition was seamless, allowing him to continue his work with minimal downtime and access to a fully equipped lab and skilled personnel. Crescenta Biosciences stands at a critical threshold, having successfully completed regulatory testing in 2022, they are now at the pre-clinical trial stage. This milestone marks a pivotal moment in their pursuit of advancing their therapeutic solutions. The future holds the promise of transformative contributions to the field of pharmaceuticals as Crescenta Biosciences continues to navigate the intricate path of drug development.
16 University Lab Partners 2023 Annual Report | Breakthroughs Today, Careers Tomorrow
Made with FlippingBook - Online catalogs